Physician profile
Jacob Vella
NPI 1467603670
$28,466.55
in general payments reported to CMS, 2019-2025
37 companies · $1,981 in 2025
The $1,981 reported for 2025 was more than what 78% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,739 · 2020: $1,729 · 2021: $3,954 · 2022: $2,974 · 2023: $4,310 · 2024: $12K · 2025: $1,981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,624 · Food and Beverage: $6,925 · Travel and Lodging: $2,489 · Education: $32.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,623.75 |
| Food and Beverage | $6,924.89 |
| Travel and Lodging | $2,489.04 |
| Education | $32.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $21,525.06 | 2019-2025 | Proclaim, Eterna, Prodigy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,031.15 | 2021-2025 | Relistor |
| Si-Bone, INC. | $838.64 | 2024-2025 | |
| Boston Scientific Corporation | $523.78 | 2019-2025 | Infinion 16 |
| Stimwave Technologies Incorporated | $359.86 | 2019 | |
| Forte Bio-Pharma LLC | $359.11 | 2022-2024 | Prolate, Nalocet |
| Collegium Pharmaceutical, INC. | $332.10 | 2019-2025 | Belbuca, Xtampza |
| Medtronic, INC. | $251.98 | 2021-2022 | |
| Nevro Corp. | $251.90 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $232.92 | 2019-2024 | Ztlido |
| Abbvie INC. | $176.46 | 2021-2024 | Botox |
| Teva Pharmaceuticals USA, INC. | $163.48 | 2019-2021 | |
| Curonix LLC | $144.58 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Amgen INC. | $143.02 | 2019-2022 | |
| Medtronic USA, INC. | $132.51 | 2020 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Vella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.